Antihypertensive Drugs Market Projected to Hit $30.9B by 2035, Driven by Patient Volume Growth
Event summary
- The global antihypertensive drugs market was valued at $21.49 billion in 2025 and is projected to reach $30.92 billion by 2035, representing a CAGR of 3.70%.
- North America held the largest regional share at 34.0% in 2025, while Asia Pacific is expected to record the fastest growth at 4.69% annually.
- Angiotensin II receptor blockers led drug classes with 30.0% of 2025 spending.
- Oral medicines represented 94.0% of route revenue, with retail pharmacies accounting for 62.0% of dispensing-related revenue.
- AstraZeneca's Baxfendy received U.S. approval in May 2026 as an add-on treatment for adults with uncontrolled hypertension.
The big picture
The antihypertensive drugs market is poised for steady growth driven by patient volume expansion rather than price increases. The market is characterized by a high volume of generics and long-term outpatient use, with innovation focused on combination formulations and treatments for resistant hypertension. Regional dynamics, particularly the rapid growth in Asia Pacific, will play a crucial role in shaping the market's future.
What we're watching
- Patient Volume Expansion
- How the expansion of primary care and community blood pressure screening will impact diagnosis and treatment initiation rates.
- Innovation in Resistant Hypertension
- Whether AstraZeneca's Baxfendy and other novel mechanisms can sustain a premium segment in a market dominated by generics.
- Regional Growth Dynamics
- The pace at which Asia Pacific, particularly China and India, will contribute to the market's fastest growth at 4.69% annually.
Related topics
